Jefferson University Hospitals

Physician Profile

Ralph Zinner, MD

Jefferson University Physician

Academic Title: Professor

Medical Oncology
Medical Oncology - Head & Neck Cancer
Medical Oncology - Lung Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital


  • Georgetown University School of Medicine, Medical School


  • Thomas Jefferson University Hospital


  • Thomas Jefferson University Hospital


  • MD Anderson Cancer Center, Houston, TX


Recent Publications

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies

Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes

Multiplex KRAS G12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials

Activity of c-Met/ALK inhibitor crizotinib and multi-kinase VEGF inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor harboring EWSR1-CREB1 fusion

TP53 alterations correlate with response to VEGF/VEGFR inhibitors: Implications for targeted therapeutics

Cancer therapy directed by comprehensive genomic profiling: A single center study

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience

BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

Systemic therapy for echinoderm microtubule-associated proteinlike 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors

Phase i combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

STUMP un"stumped": Anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors